Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 5;7(4):178-185.
doi: 10.18683/germs.2017.1124. eCollection 2017 Dec.

Observed HIV drug resistance associated mutations amongst naïve immunocompetent children in Yaoundé, Cameroon

Affiliations

Observed HIV drug resistance associated mutations amongst naïve immunocompetent children in Yaoundé, Cameroon

George Mondinde Ikomey et al. Germs. .

Abstract

Introduction: The emergence of drug resistance mutations (DRMs) has been a major threat for successful lifelong combination antiretroviral therapy (cART), especially for HIV-vertically infected children within the context of the prevention of mother-to-child transmission (PMTCT). This study aimed to evaluate DRMs amongst immune competent treatment-naïve children in Cameroon.

Methods: A cross-sectional study was conducted between 2015 and 2016 amongst 55 proxy consented HIV-1 positive children, aged 9 months to 6 years. They were all immune competent, cART naïve and with unknown history of PMTCT. CD4 cell counts and genotypic drug resistance testing were performed using standard methods.

Results: Levels of DRMs to protease (PR) inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs were 27.6%, 3.7% and 40.7%, respectively. Only minor DRMs were observed for PR. The observed mutations for NRTI were K65R, T215I and K219E (33.0% each) and for NNRTI: V106M, Y181C and Y188H (6.0% each). Only minor accessory mutations were found in the integrase (IN) region.

Conclusion: Despite widely available cART we still observe naïve HIV children, especially from the rural communities. We observe that a proportion of study participants had HIV-1 drug resistance associated mutations (RAMs). Data generated could help strengthen the current PMTCT programmes within the country. There is a need to upscale approaches for drug resistance testing for children in Cameroon and many other resource-limited settings.

Keywords: Cameroon; HIV; immune competent; infants; prevention of mother-to-child-transmission (PMTCT); resistance; treatment-naïve.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: All authors – none to disclose.

Figures

Figure 1.
Figure 1.. A map of the different health districts around Yaoundé, Cameroon.
The samples were obtained from the 5 different health districts surrounding the CSCCD and the University of Yaoundé I, Cameroon. The map was created with scribble maps (www.scribblemaps.com).

References

    1. World Health Organization (WHO) Cameroon country report. 2015. [Accessed on: 17 March 2017]. Available at: http://www.who.int/countries/cmr/en/
    1. Budambula V, Musumba FO, Webale MK, et al. HIV-1 protease inhibitor drug resistance in Kenyan antiretroviral treatment-naive and -experienced injection drug users and non-drug users. AIDS Res Ther. 2015;12:27. - PMC - PubMed
    1. UNAIDS/WHO working group on global HIV/AIDS & STD surveillance. 2013/2015 . AIDS epidemic update. Geneva, Switzerland: UNAIDS; 2015.
    1. Takow SE, Atashili J, Enow-Tanjong R, et al. Time for Option B+? Prevalence and characteristics of HIV infection among attendees of 2 antenatal clinics in Buea, Cameroon. J Int Assoc Provid AIDS Care. 2015;14:77–81. - PubMed
    1. Billong SC, Fokam J, Aghokeng AF, et al. Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance. PLoS One. 2013;8:e72680. - PMC - PubMed

LinkOut - more resources